Recently Featured

Odyssey Therapeutics Resubmits IPO Plans Amid Improved Market Conditions

April 23, 2026
Odyssey Therapeutics has officially submitted its second attempt at an initial public offering (IPO), nearly a year after retracting its first effort due to unfavorable market conditions. The Boston-based biotech company filed its IPO paperwork on Friday, signaling a renewed confidence in its market strategy as conditions appear to be warming up. This renewed attempt…

AACR 2026: More strong data for Revolution Medicines’ KRAS drug

April 23, 2026
At the AACR 2026 annual meeting in San Diego, Revolution Medicines presented compelling new data on its KRAS-targeted therapy, further solidifying its position in the competitive oncology landscape. This development is particularly significant as KRAS mutations have long been considered challenging targets in cancer treatment. The data presented indicates not only enhanced efficacy but also…

10x Genomics Launches Atera Spatial Platform at AACR Meeting

April 23, 2026
10x Genomics has officially launched its highly anticipated Atera spatial platform during the American Association for Cancer Research (AACR) meeting in San Diego. The announcement was made at a celebratory event, marking a significant milestone for the company and the genomics community at large. CEO Serge Saxonov emphasized that the Atera addresses a critical gap…

Quality Metrics Program Aims to Enhance Pharmaceutical Manufacturing Standards

April 23, 2026
The FDA has launched a Quality Metrics Data Reporting program aimed at improving the overall quality of drug manufacturing. This initiative is designed to identify and address prevalent quality issues within the pharmaceutical sector, which have contributed to ongoing product shortages and regulatory challenges. By promoting a standardized approach to quality metrics, the FDA seeks…

Ongoing Cases